Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
H.C. Wainwright Sticks to Their Buy Rating for Genmab (GMAB)
12:08pm, Monday, 30'th Mar 2020
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
12:35pm, Thursday, 26'th Mar 2020
Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured
Hedge Funds Have Never Been This Bullish On Genmab A/S (GMAB)
07:51pm, Tuesday, 17'th Mar 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Hedge Funds Were Buying Cardinal Health, Inc. (CAH) Before The Coronavirus
07:48pm, Tuesday, 17'th Mar 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Hedge Funds Have Never Been More Bullish On Agnico Eagle Mines Limited (AEM)
07:47pm, Tuesday, 17'th Mar 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Hedge Funds Were Flocking Into Brookfield Infrastructure Partners L.P. (BIP) Before The Coronavirus
07:47pm, Tuesday, 17'th Mar 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Genmab: An Attractive Biotechnology Platform Pick In March 2020
05:11pm, Monday, 16'th Mar 2020
Darzalex is a major revenue driver for Genmab. The company may start earning significant revenues from other approved products as well as from pipeline products
Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from international companies wit
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
01:33pm, Friday, 13'th Mar 2020
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but
CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella
07:06am, Friday, 13'th Mar 2020
German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
12:46pm, Friday, 21'st Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose B
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
12:06pm, Thursday, 20'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia
Andreas Halvorsen Trims Adaptive Biotechnologies Stake
04:27pm, Monday, 03'rd Feb 2020
The immune-driven biotech company went public last June Continue reading...
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) Head-To-Head Comparison
08:25am, Monday, 27'th Jan 2020
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, ea
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) Financial Review
07:31am, Saturday, 25'th Jan 2020
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recomm
